This Medudy course is a video tutorial for physicians on the topic of "Lenacapavir for HIV prevention in cisgender women". The format used here is a so-called "Journal Club Summary", in which we summarize the latest and most clinically relevant studies for you.
Cisgender women account for a significant proportion of HIV infections worldwide each year. However, acceptance, adherence and long-term use among women remain low, highlighting the need for alternative options for prophylaxis.
Lenacapavir is a novel capsid inhibitor with a long half-life that allows for twice-yearly subcutaneous injections instead of daily oral administration. Today's study investigated the safety and efficacy of pre-exposure prophylaxis with twice-yearly lenacapavir and daily medication in adolescent girls and young women.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
At the end of this course you will know
- the clinical background and relevance of the research question under investigation
- the study design and methodology of the publication to answer the research question
- the results and key takeaways of the publication
- the conclusion of the publication and possible limitations
